United States · Biotechnology startup
United States · Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.
Funding reportedLast round: Post-IPO Debt
What company datasets say Ultragenyx Pharmaceutical raised
Funding, as reported
Reported in all$400Min dollars
Last roundPost-IPO Debt
Investors listed5
SEC Form D$109M sold, 4 filings, last Dec 2012
Founders and team
From the SEC filings it signed: 7 on the team.
- Cordelia D. LeonardExecutive Officeri
- Emil D. KakkisExecutive Officer, Directori
- John D. DittonExecutive Officeri
- Shalini D. SharpExecutive Officeri
- Steven D. JunglesExecutive Officeri
- Thomas D. KassbergExecutive Officeri
- Vimal D. SrivastavaExecutive Officeri
On the board, as filediBen D. AuspitzEran D. NadavMarten D. SteenWilliam D. Aliski
Biotechnology in United States
Startups like it
- SojournixWaltham · founded 2016Raised
- Receptor Life SciencesSeattle · founded 2017Raised
- Attune PharmaceuticalsNew York · founded 2018Raised
AbbVieNorth Chicago · founded 2012
GrailMenlo Park · founded 2015
EQRxCambridge · founded 2019- Cerevel TherapeuticsBoston · founded 2018
Royalty PharmaNew York · founded 1996
Is this your company?
Add your raise, your deck and your story, and put Ultragenyx Pharmaceutical in front of investors. Or tell us what we have wrong.